STAT

GSK partners with CRISPR pioneer Doudna to search for new drugs

CRISPR pioneer Jennifer Doudna and CRISPR researcher Jonathan Weissman will work with GlaxoSmithKline in a new Bay Area drug discovery lab.
Jennifer Doudna, CRISPR developer and University of California, Berkeley, scientist. Source: Vincent Yu/AP

SAN FRANCISCO — The drug maker GlaxoSmithKline announced Thursday that it would team up with some of the nation’s most prominent CRISPR researchers to use the gene-editing technology in a search for new medicines, establishing a new lab in San Francisco and spending up to $67 million over five years.

Jennifer Doudna, the University of California, Berkeley, researcher who co-invented the CRISPR enzyme technology, will help lead the effort, along with Jonathan Weissman, a UC San Francisco researcher

You're reading a preview, sign up to read more.

More from STAT

STAT4 min read
How The Drug Industry Keeps Winning In Washington
D.C. Diagnosis is STAT’s weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox. What if I told you the Sen. Thom Tillis campaign account was graced with nearly $20,000 in personal donations f
STAT5 min read
In A Small Study, A Cancer Vaccine Assist Beats Immunotherapy Drugs Alone
The largest study to date of a "cancer vaccine" found that combining it with an immunotherapy drug kept patients’ tumors in check longer, on average, than the drug alone.
STAT4 min readScience
HIV’s Genetic Code, Extracted From A Nub Of Tissue, Adds To Evidence Of Virus’ Emergence In Humans A Century Ago
In a nub of issue from the 1960s, scientists have found more clues of HIV’s emergence in humans.